Walleye Capital LLC Zentalis Pharmaceuticals, Inc. Transaction History

Walleye Capital LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$4.09 - $16.13 $90,065 - $355,198	22,021 New	22,021 $90,000
Q3 2022 Nov 14, 2022	BUY	$20.23 - $31.73 $1.73 Million - $2.71 Million	85,529 New	85,529 $1.85 Million
Q2 2022 Aug 08, 2022	SELL	$17.91 - $52.25 $366,349 - $1.07 Million	-20,455 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$41.58 - $80.89 $295,924 - $575,694	7,117 Added 53.36%	20,455 $944,000
Q4 2021 Mar 03, 2022	BUY	$66.92 - $84.79 $892,578 - $1.13 Million	13,338 New	13,338 $1.12 Million

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $171M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.